The fair value range that analysts use for Adicet Bio has been revised from about US$34.83 to US$29.00. This change resets where many models now anchor the stock. The revision is linked directly to the latest prula cel data in systemic lupus erythematosus and lupus nephritis, as well as differing views on how much of that potential is already captured in the current share price. As you read on, you will see how this evolving narrative may influence how you track Adicet Bio from here. Analyst...
REDWOOD CITY, Calif., October 30, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on October 30, 2026.
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%
Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026.
Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
This is the newest page. Registered accounts read further back.